Geri Dön

Hematopoietic stem cell genetherapy with CRISPR/Cas9 inmetachromatic leukodystrophy(MLD)

Başlık çevirisi mevcut değil.

  1. Tez No: 723868
  2. Yazar: MERVE KAFTANCIOĞLU
  3. Danışmanlar: Belirtilmemiş.
  4. Tez Türü: Yüksek Lisans
  5. Konular: Tıbbi Biyoloji, Medical Biology
  6. Anahtar Kelimeler: Belirtilmemiş.
  7. Yıl: 2018
  8. Dil: İngilizce
  9. Üniversite: Unıversıtı Malaya Um
  10. Enstitü: Yurtdışı Enstitü
  11. Ana Bilim Dalı: Belirtilmemiş.
  12. Bilim Dalı: Belirtilmemiş.
  13. Sayfa Sayısı: Belirtilmemiş.

Özet

Özet yok.

Özet (Çeviri)

Background: Metachromatic leukodystrophy (MLD) is a familial progressive neurologic dysfunction due to Arylsulfatase A (ASA) enzyme deficiency. The unfunctional enzyme cannot carry out its normal lysosomal process for sulfatides, therefore it leads neurodegeneration with a temporal decline. The one of the propitious therapy option is through lentiviral-mediated autologous transplantation of Hematopoietic Stem Cells (HSC) that targets the primary nervous system manifestations; however insertional mutagenesis due to random is a risk that cannot be disregarded. Thus, we have chosen to study an approach that combines autologous HSC Transplantation (HSCT) with CRISPR/Cas9 system and non-integrating repair templates to ensure target integration and thereby create a safe gene therapy. Methods: We assessed the ASA expression and enzyme activity in CD34+ HSCs. We utilized plasmid-encoded CRISPR/Cas9 system to target three specific mutations in ARSA gene locus in K562 cells. In addition, we used CRISPR/Cas9 system (encoded as mRNA/protein) and single-stranded DNA (ssDNA) repair template to integrate reporter protein/ARSA cDNA into the endogenous locus in CD34+ HSCs. The efficiency of integration was measured by reporter protein expression. Results: Our results demonstrated that CD34+ HSCs expresses enzymatically active Arylsulfatase A. Our designed sgRNAs targeting the three mutation sites of ARSA revealed that targeted indels induction in K562 is lower (up to 30%) due to plasmid encoded CRISPR/Cas9 system. The mRNA/protein encoded CRISPR/Cas9 system exhibited the improved efficacy in both K562 (up to 86%) and CD34+ HSCs (up to 56%). We found that out of the five tested sgRNAs, three of them resulted in moderate knockout efficacy (> 40%). The gene-repair quantification by flow cytometry showed that up to 3% site-specific integration of iv reporter gene was achieved at ARSA locus using Cas9 protein and single stranded DNA (ssDNA) in CD34+ HSCs. Conclusion: Our approach provides guidance on non-viral gene-correction in CD34+ HSCs using Cas9 protein and ssDNA. However, further optimization is indispensable to increase the homology directed repair (HDR) to attain a clinical benefit for MLD.

Benzer Tezler

  1. Kronik miyeloid lösemide CRISPR/CAS9 aracılı yeni nesil gen tedavisi

    A new generation gene treatment of chronic myeloid leukemia through the mediation of CRISPR/cas9

    MAKBULE NİHAN SOMUNCU

    Doktora

    Türkçe

    Türkçe

    2020

    HematolojiNecmettin Erbakan Üniversitesi

    Tıbbi Genetik Ana Bilim Dalı

    PROF. DR. MAHMUT SELMAN YILDIRIM

  2. Mezenşimal kök hücrelerin immün modülatör etkisinin hemofagositik sendrom klinik uygulamalarına temel oluşturmak üzere in vitro modelde incelenmesi

    Investigation of the immune modulator effect of mesenchymal stem cells in in vitro model as the basis for hemophagocytic syndrome clinical applications

    HANDAN SEVİM

    Doktora

    Türkçe

    Türkçe

    2015

    BiyolojiHacettepe Üniversitesi

    Biyoloji Ana Bilim Dalı

    DOÇ. DR. ÖZER AYLİN GÜRPINAR

  3. Hematopoetik kök hücre gen tedavi kültür koşulları ve engrafman optimizasyonu

    Optimization of hematopoietic stem cell gene therapy culture conditions and engraftment

    MEHMET EMİN ŞEKER

    Yüksek Lisans

    Türkçe

    Türkçe

    2021

    Allerji ve İmmünolojiHacettepe Üniversitesi

    Kök Hücre Ana Bilim Dalı

    DOÇ. DR. FATİMA SUSANNA FAUSTİNA AERTS KAYA

  4. AML kasumi-3 ve KG-1 hücre hatlarında hücre polaritesindeki değişiklikler ve in vitro hedef tedavisinin etkileri

    Changes in cell polarity in aml kasumi-3 and KG-1 cell lines and the effects of in vitro target treatment

    RASHAD RASULOV

    Doktora

    Türkçe

    Türkçe

    2019

    OnkolojiEge Üniversitesi

    Kök Hücre Ana Bilim Dalı

    PROF. DR. AFİG BERDELİ

  5. Assessment of the antioxidative and antiapoptotic effects of delta-opioid peptide D-ALA2-leu5-enkephalin on survival on hematopoietic stem cells

    Delta-opioid peptide D-ALA-LEU5-enkephalin'in hematopoetik kök hücrelerin sağ kalımındaki rolü ve antioksidatif ve antiapoptotik etkilerinin araştırılması

    AYNURA MAMMADOVA

    Yüksek Lisans

    İngilizce

    İngilizce

    2019

    HematolojiHacettepe Üniversitesi

    Kök Hücre Ana Bilim Dalı

    DR. ÖĞR. ÜYESİ FATİMA SUSANNA FAUSTİNA AERTS KAYA